Mirum's brelovitug achieves Phase III primary endpoint with 56% composite response in chronic hepatitis delta virus. Read the ...
ADARx Pharmaceuticals advances siRNA therapeutics for rare genetic and complement-mediated diseases. Discover their ...
Roche and Atavistik Bio collaborate on allosteric small molecules for cardiovascular and metabolic disease. Discover the strategic partnership details.
Tolerance Bio expands thymus pipeline with TLB-33 anti-IL-33 antibody license from Tanabe Pharma. Up to $560M deal. Read the latest biotech news.
AbbVie's Juvmo (tavapadon) receives FDA approval as the first selective D1/D5 agonist for Parkinson's disease treatment.
Merck licenses SPR2015 KRAS G12D inhibitor from SciBrunch for $400M upfront. Deal valued at $2.13B with milestone payments.
Chroma Bio's CRMA-1001 epigenetic silencer therapy demonstrates sustained HBV suppression in preclinical models. Read the ...
FDA approves Gazyva (obinutuzumab) to reduce relapse risk in pediatric idiopathic nephrotic syndrome patients 2+ years old.
Incyte takes FDA approval for Atebrioz as first oral ALK2i for fibrodysplasia ossificans progressiva
FDA approves Atebrioz (zilurgisertib), the first oral ALK2 inhibitor for fibrodysplasia ossificans progressiva. Learn about this breakthrough treatment.
Prime Medicine receives FDA IND clearance for PM647, a one-time gene editing therapy for alpha-1 antitrypsin deficiency.
Amplifyer Bio's AM-01 achieves up to 100-fold increase in circulating tumor DNA recovery. Breakthrough preclinical data ...
Scancell Holdings secures $25M debt facility from BlackRock to fund Phase III iSCIB1+ melanoma immunotherapy trial. Discover ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results